MAM
CASC

Meeder Asset Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

Meeder Asset Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,014
Closed -$4K – 1844
2017
Q2 		$4K Buy
+1,014
New +$4.02K ﹤0.01% 1298

Other funds holding CASC

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
SH
Sandia Holdings Greenwich, Connecticut $213M AUM 29.35% 1-Year Est. Return

Meeder Asset Management's CASC Position: Q3 2017 in Review

Meeder Asset Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q3 2017, closing a stake of 1,014 shares — an estimated $4K sold.

Meeder Asset Management first reported a position in CASC in Q2 2017 and held it in 1 quarter. The position peaked at $4K in Q2 2017. 79 funds tracked by Wall St. Rank hold CASC as of Q3 2017.

  • Meeder Asset Management reported no remaining Cascadian Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Meeder Asset Management sold 1,014 Cascadian Therapeutics, Inc. shares in Q3 2017, an estimated $4K.
  • Meeder Asset Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2017 and held it in 1 quarter.
  • Meeder Asset Management's Cascadian Therapeutics, Inc. position peaked at $4K in Q2 2017.
  • 79 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q3 2017.

Based on Meeder Asset Management's 13F filing for Q3 2017, filed 20 Oct 2017.